The role of anti–IL-2 receptor in high-risk kidney transplant patients
- 1 September 2004
- journal article
- research article
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (7) , 2110-2112
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996New England Journal of Medicine, 2000
- REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2Transplantation, 1999
- REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1Transplantation, 1999
- Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantationKidney International, 1998
- A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1998
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- Relevant targets for therapy with monoclonal antibodies in allograft transplantationKidney International, 1994
- THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG-TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2Transplantation, 1994
- THE IMPACT OF ACUTE REJECTION EPISODES ON LONG-TERM GRAFT FUNCTION AND OUTCOME IN 1347 PRIMARY RENAL TRANSPLANTS TREATED BY 3 CYCLOSPORINE REGIMENSTransplantation, 1993